Prevalence of dysphagia and screening tools in patients with Parkinson’s disease
Objective: Determine the prevalence of dysphagia in patients with Parkinson's disease (PD) and compare the Swallowing Disturbance Questionnaire (SDQ) and Eating Assessment Tool (EAT-10). Background:…Phenotype of Parkinson’s Disease in African Americans Using NIH Toolbox Motor Measures
Objective: To determine phenotypic differences using qualitative and quantitative measures between African American (AA) and white (W) patients with Parkinson’s disease (PD) at Rush University…Relationship between tumor and very slow Parkinson`s disease progression
Objective: We evaluate the Parkinson`s disease patients with very slow progression. One of their clinical features are the medical history of tumor. Background: Some cancer…Dietary and Plasma Polyunsaturated Fatty Acids in Parkinson’s Disease
Objective: We assessed the dietary intakes and plasma levels of polyunsaturated fatty acid (PUFA) in Parkinson's disease (PD), and their relation to motor and non-motor…Homer1 polymorphism in patients with Parkinson’s disease and psychosis
Objective: To explore the association of psychosis in Parkinson’s disease with polymorphisms of HOMER1, a gene whose product (Homer1) is responsible for modulating the metabotropic…Determination of non-motor symptoms in Parkinson’s disease in Kazakhstan (on the example of the city of Almaty)
Objective: To identify non-motor symptoms in patients with Parkinson's disease, depending on the severity of the disease. Background: Parkinson's disease is a chronic disease, as…CVT-301 treatment provides consistent and clinically significant improvements in Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) over 12 weeks
Objective: A post hoc analysis of UPDRS-III sequential changes over the 12-week treatment period of a phase 3 study. Background: CVT-301 is an inhaled levodopa…Phase I-II first-in-human clinical trial of intraputamenal CDNF in Parkinson’s disease: Exploratory fluid-based biomarker endpoints of the 12-month treatment period
Objective: To explore fluid-based biomarkers in subjects with advanced idiopathic Parkinson’s disease (PD) before and after intermittent intraputamenal monthly infusions of CDNF. Background: CDNF is…Parkinson Progression Marker Initiative 2.0 – New Science/New Cohorts
Objective: The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes,…The UP study – Ursodeoxycholic acid (UDCA) as neuroprotective treatment for Parkinson’s disease
Objective: To determine the safety and tolerability of ursodeoxycholic acid (UDCA) in Parkinson’s disease (PD) and explore its neuroprotective potential. Background: We previously undertook the…
- « Previous Page
- 1
- …
- 41
- 42
- 43
- 44
- 45
- …
- 149
- Next Page »